<DOC>
	<DOCNO>NCT01230411</DOCNO>
	<brief_summary>This pilot trial collect data use intravenous ibuprofen ( IVIb ) treatment acute migraine attack . Data collect efficacy IVIb subject treat study medication 2 72 hour time onset headache . Periodic safety efficacy assessment perform prior study drug administration . Null hypothesis : There difference proportion subject 2 treatment group ( active treatment placebo ) pain relief 2 hour completion double-blind treatment infusion . Pain relief define reduction headache pain level severe moderate decrease mild headache-free , respectively .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled Pilot Study Collect Evaluate Data Use Intravenous Ibuprofen Treatment Acute Migraine Attack</brief_title>
	<detailed_description>This pilot trial collect evaluate data use intravenous ibuprofen ( IVIb ) treatment acute migraine attack . Data collect efficacy IVIb subject treat study medication 2 72 hour time onset headache . Periodic safety efficacy assessment perform prior study drug administration . Null hypothesis : There difference proportion subject 2 treatment group ( active treatment placebo ) pain relief 2 hour completion double-blind treatment infusion . Pain relief define reduction headache pain level severe moderate decrease mild headache-free , respectively .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Male female subject age 18 65 , inclusive Subject diagnose episodic migraine , without aura accord ICHD2 criterion least oneyear prior screening Subject experience 210 migraine attack per month ( previous 6 month ) 15 day headache per month . Subject use agrees use duration participation medically acceptable form contraception ( determined investigator ) , female childbearing potential Subject able come 4 hour inclinic treatment acute migraine attack Subjects able understand comply study procedure . Subject provide write informed consent prior screen procedure conduct If subject allowable migraine preventive medication , dose stable least 4 week prior screen dose remain stable throughout study participation . Unable make reliable selfreport pain intensity pain relief Use analgesic opioid within 24 hour onset headache treat study medication . ( If subject eligible headache take triptan DHE within 24 hour , great 2 hour study drug dosing , treat study medication . ) Patients take follow medication regular basis : warfarin , lithium , ACEinhibitors , loop diuretic , thiazide diuretic , ARBs , methotrexate . Patients active , clinically significant anemia Patients history evidence asthma Patients history heart failure Subjects severely impair hepatic renal function , determine investigator Patients history allergy hypersensitivity component IVIb , aspirin ( aspirin relate product ) , NSAIDs , COX2 inhibitor Pregnant nursing woman Patients history congenital bleeding diathesis ( e.g. , hemophilia ) active clinically significant bleeding , underlie platelet dysfunction include ( limited ) idiopathic thrombocytopenic purpura , disseminate intravascular coagulation , congenital platelet dysfunction Patients GI bleeding require medical intervention within previous 6 week ( unless definitive surgery perform . ) Patients platelet count less 100,000 , determine within 28 day prior treatment Preexisting current dependence opioids . Subjects participate investigational drug trial 30 day prior screen visit Subjects uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Episodic migraine</keyword>
</DOC>